At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 100 enrolled
Drug / intervention
IMR-687 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study of IMR-687 in Adult Patients With Sickle Cell Anaemia (Homozygous HbSS or Sickle-β0 Thalassemia)
In Brief
A Phase 2 clinical trial evaluating IMR-687 and Placebo for Sickle Cell Disease. Completed, enrolled 100 participants across 13 sites in 2 countries.
Detailed Summary
Study of IMR-687 in adult participants with sickle cell anemia (SCA) (homozygous HbSS or sickle-β0 thalassemia).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSickle Cell Disease
CountriesUnited Kingdom, United States
CollaboratorsImara, Inc.
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedJan 2018
Enrollment StartJan 2018
Primary CompletionAug 2020
TodayJul 2026
First PostedJan 17, 2018
Enrollment StartJan 26, 2018
Primary CompletionAug 28, 2020
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 8.5 years ago
Interventions
IMR-687drug
Oral administration of IMR-687 once daily with or without HU.
Placebodrug
Oral administration of placebo once daily with or without HU.